Drug Insights

Using Synapse for Your Cefdinir Research: An Easy Guide

11 February 2024
2 min read

Cefdinir, marketed under the brand name Omnicef, is a small molecule drug that acts as a penicillin-binding protein (PBP) inhibitor and a cell wall inhibitor. It is indicated for the treatment and prevention of infections caused by susceptible bacteria. Cefdinir works by inhibiting the growth and multiplication of bacteria that cause infections, including streptococcus, staphylococcus, and Haemophilus influenzae. It is approved in several countries, including the US, China, Japan, and South Korea. Omnicef is available as capsules or an oral suspension and is typically administered once or twice daily depending on the severity of the infection. It is important to use this medication only for the treatment or prevention of bacterial infections, as overuse or misuse can lead to the development of drug-resistant bacteria. Click on the image below to begin the exploration journey of Cefdinir through the Synapse database!

图形用户界面, 应用程序, 电子邮件

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

FDA Approves NeuroBo Pharmaceuticals' Phase 1 Study of Obesity Drug DA-1726
Latest Hotspot
3 min read
FDA Approves NeuroBo Pharmaceuticals' Phase 1 Study of Obesity Drug DA-1726
11 February 2024
NeuroBo Pharmaceuticals has received approval from the FDA for a Phase 1 clinical study of DA-1726, a new drug aimed at managing obesity.
Read →
Accessing Fluconazole Information on Synapse: A Step-by-Step Approach
Drug Insights
2 min read
Accessing Fluconazole Information on Synapse: A Step-by-Step Approach
11 February 2024
Fluconazole is a small molecule drug used to treat various fungal infections. It is sold under the trade names Diflucan, Zoltec, and Loitin.
Read →
Halia Therapeutics Revels $30M Series C Funding for Inflammation Treatments
Latest Hotspot
3 min read
Halia Therapeutics Revels $30M Series C Funding for Inflammation Treatments
11 February 2024
Halia Therapeutics has unveiled a $30 million Series C funding round to further develop their innovative range of treatments for inflammation.
Read →
Maximize Your Synapse Use: Your Guide to Searching Meclizine
Drug Insights
2 min read
Maximize Your Synapse Use: Your Guide to Searching Meclizine
11 February 2024
Meclizine is a small molecule drug that acts as an antagonist of histamine (H1) receptors.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.